BRCA1, PARP, and 53BP1: Conditional synthetic lethality and synthetic viability

Journal of Molecular Cell Biology

Volumn 3, Issue 1, 2011, Pages 66-74

  Aly, Amal ^a   Ganesan, Shridar ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

53BP1; BRCA1; DNA repair; PARP

Indexed keywords

EID: 79951501575     PISSN: 16742788     EISSN: 17594685     Source Type: Journal    
DOI: 10.1093/jmcb/mjq055     Document Type: Article

References (109)

1. Abbott, D. W., Thompson, M. E., Robinson-Benion, C., et al. (1999). BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem. 274, 18808-18812.
2. Ahel, I., Ahel, D., Matsusaka, T., et al. (2008). Poly (ADP-ribose)-binding zinc finger motifs in DNA repair/checkpoint proteins. Nature 451, 81-85.
3. Ahel, D., Horejsi, Z., Wiechens, N., et al. (2009). Poly (ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325, 1240-1243.
4. Allinson, S. L., Dianova, II, and Dianov, G. L. (2003). Poly (ADP-ribose) polymerase in base excision repair: always engaged, but not essential for DNA damage processing. Acta Biochim. Pol. 50, 169-179. (Pubitemid 37034238)
5. Ame, J. C., Rolli, V., Schreiber, V., et al. (1999). PARP-2, a novel mammalian DNA damage-dependent poly (ADP-ribose) polymerase. J. Biol. Chem. 274, 17860-17868.
6. Ashworth, A. (2008a). Drug resistance caused by reversion mutation. Cancer Res. 68, 10021-10023.
7. Ashworth, A. (2008b). A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790.
8. Audeh, M. W., Carmichael, J., Penson, R. T., et al. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245-251.
9. Bau, D. T., Mau, Y. C., and Shen, C. Y. (2006). The role of BRCA1 in nonhomologous end-joining. Cancer Lett. 240, 1-8.
10. Bouwman, P., Aly, A., Escandell, J. M., et al. (2010). 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688-695.
11. Bryant, H. E., and Helleday, T. (2006). Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res. 34, 1685-1691.
12. Bunting, S. F., Callen, E., Wong, N., et al. (2010). 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254.
13. Byrski, T., Huzarski, T., Dent, R., et al. (2009). Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 115, 359-363.
14. Byrski, T., Gronwald, J., Huzarski, T., et al. (2010). Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J. Clin. Oncol. 28, 375-379.
15. Cantor, S. B., Bell, D. W., Ganesan, S., et al. (2001). BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105, 149-160. (Pubitemid 32323924)
16. Cao, L., Li, W., Kim, S., et al. (2003). Senescence, aging, and malignant transformation mediated by p53 in mice lacking the Brca1 full-length isoform. Genes Dev. 17, 201-213. (Pubitemid 36105893)
17. Cao, L., Xu, X., Bunting, S. F., et al. (2009). A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell 35, 534-541.
18. Chen, L., Nievera, C. J., Lee, A. Y., et al. (2008). Cell cycle-dependent complex formation of BRCA1. CtIP. MRN is important for DNA double-strand break repair. J. Biol. Chem. 283, 7713-7720.
19. Chou, D. M., Adamson, B., Dephoure, N. E., et al. (2010). A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc. Natl. Acad. Sci. USA 107, 18475-18480.
20. Cressman, V. L., Backlund, D. C., Avrutskaya, A. V., et al. (1999a). Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. Mol. Cell. Biol. 19, 7061-7075. (Pubitemid 29441888)
21. Cressman, V. L., Backlund, D. C., Hicks, E. M., et al. (1999b). Mammary tumor formation in p53-and BRCA1-deficient mice. Cell Growth Differ. 10, 1-10. (Pubitemid 29086913)
22. Difilippantonio, S., Gapud, E., Wong, N., et al. (2008). 53BP1 facilitates longrange DNA end-joining during V (D) J recombination. Nature 456, 529-533. (Pubitemid 50304846)
23. Ding, S., Wu, X., Li, G., et al. (2005). Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice. Cell 122, 473-483. (Pubitemid 41127147)
24. El-Khamisy, S. F., Masutani, M., Suzuki, H., et al. (2003). A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31, 5526-5533. (Pubitemid 37441922)
25. Farmer, H., McCabe, N., Lord, C. J., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921. (Pubitemid 40559006)
26. Fernandez-Capetillo, O., Chen, H. T., Celeste, A., et al. (2002). DNA damage-induced G2-M checkpoint activation by histone H2AX and 53BP1. Nat. Cell Biol. 4, 993-997. (Pubitemid 35469431)
27. Fong, P. C., Boss, D. S., Yap, T. A., et al. (2009). Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134.
28. Fong, P. C., Yap, T. A., Boss, D. S., et al. (2010). Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519.
29. Gottipati, P., Vischioni, B., Schultz, N., et al. (2010). Poly (ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells. Cancer Res. 70, 5389-5398.
30. Gottschalk, A. J., Timinszky, G., Kong, S. E., et al. (2009). Poly (ADP-ribosyl) ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl. Acad. Sci. USA 106, 13770-13774.
31. Gowen, L. C., Johnson, B. L., Latour, A. M., et al. (1996). Brca1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nat. Genet. 12, 191-194. (Pubitemid 26051301)
32. Greenberg, R. A., Sobhian, B., Pathania, S., et al. (2006). Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev. 20, 34-46. (Pubitemid 43042666)
33. Hakem, R., de la Pompa, J. L., Sirard, C., et al. (1996). The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85, 1009-1023. (Pubitemid 26231168)
34. Hakem, R., de la Pompa, J. L., Elia, A., et al. (1997). Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nat. Genet. 16, 298-302. (Pubitemid 27280216)
35. Hartman, A. R., and Ford, J. M. (2002). BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet. 32, 180-184. (Pubitemid 34977215)
36. Helleday, T., Bryant, H. E., and Schultz, N. (2005). Poly (ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy. Cell Cycle 4, 1176-1178. (Pubitemid 41365386)
37. Hohenstein, P., Kielman, M. F., Breukel, C., et al. (2001). A targeted mouse Brca1 mutation removing the last BRCT repeat results in apoptosis and embryonic lethality at the headfold stage. Oncogene 20, 2544-2550. (Pubitemid 32531351)
38. Holstege, H., Joosse, S. A., van Oostrom, C. T., et al. (2009). High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res. 69, 3625-3633.
39. Huber, L. J., Yang, T. W., Sarkisian, C. J., et al. (2001). Impaired DNA damage response in cells expressing an exon 11-deleted murine Brca1 variant that localizes to nuclear foci. Mol. Cell. Biol. 21, 4005-4015. (Pubitemid 32476462)
40. Huyen, Y., Zgheib, O., Ditullio, R. A., Jr., et al. (2004). Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 432, 406-411. (Pubitemid 39551676)
41. Ismail, I. H., Andrin, C., McDonald, D., et al. (2010). BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J. Cell Biol. 191, 45-60.
42. Issaeva, N., Thomas, H. D., Djureinovic, T., et al. (2010). 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res. 70, 6268-6276.
43. Kass, E. M., and Jasin, M. (2010). Collaboration and competition between DNA double-strand break repair pathways. FEBS Lett. 584, 3703-3708.
44. Kim, H., Huang, J., and Chen, J. (2007). CCDC98 is a BRCA1-BRCT domainbinding protein involved in the DNA damage response. Nat. Struct. Mol. Biol. 14, 710-715. (Pubitemid 47220062)
45. King, M. C., Marks, J. H., and Mandell, J. B. (2003). Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643-646. (Pubitemid 37310920)
46. Liu, C. Y., Flesken-Nikitin, A., Li, S., et al. (1996). Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10, 1835-1843. (Pubitemid 26272388)
47. Liu, X., Holstege, H., van der Gulden, H., et al. (2007a). Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc. Natl. Acad. Sci. USA 104, 12111-12116. (Pubitemid 47185638)
48. Liu, Z., Wu, J., and Yu, X. (2007b). CCDC98 targets BRCA1 to DNA damage sites. Nat. Struct. Mol. Biol. 14, 716-720. (Pubitemid 47220064)
49. Ludwig, T., Chapman, D. L., Papaioannou, V. E., et al. (1997). Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev. 11, 1226-1241. (Pubitemid 27235356)
50. Ludwig, T., Fisher, P., Ganesan, S., et al. (2001). Tumorigenesis in mice carrying a truncating Brca1 mutation. Genes Dev. 15, 1188-1193. (Pubitemid 32472748)
51. Manie, E., Vincent-Salomon, A., Lehmann-Che, J., et al. (2009). High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res. 69, 663-671.
52. Masson, M., Niedergang, C., Schreiber, V., et al. (1998). XRCC1 is specifically associated with poly (ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 18, 3563-3571. (Pubitemid 28240528)
53. Mochan, T. A., Venere, M., Di Tullio, R. A., Jr., et al. (2003). 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxiatelangiectasia mutated (ATM) in response to DNA damage. Cancer Res. 63, 8586-8591. (Pubitemid 38064030)
54. Moynahan, M. E., Chiu, J. W., Koller, B. H., et al. (1999). Brca1 controls homology-directed DNA repair. Mol. Cell 4, 511-518. (Pubitemid 29531131)
55. Moynahan, M. E., Cui, T. Y., and Jasin, M. (2001). Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res. 61, 4842-4850. (Pubitemid 32691900)
56. Neuhausen, S. L., and Marshall, C. J. (1994). Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54, 6069-6072. (Pubitemid 24378631)
57. Oikawa, A., Tohda, H., Kanai, M., et al. (1980). Inhibitors of poly (adenosine diphosphate ribose) polymerase induce sister chromatid exchanges. Biochem. Biophys. Res. Commun. 97, 1311-1316. (Pubitemid 11148283)
58. Puppe, J., Drost, R., Liu, X., et al. (2009). BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to polycomb repressive complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res. 11, R63.
59. Reid, L. J., Shakya, R., Modi, A. P., et al. (2008). E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of doublestrand DNA breaks. Proc. Natl. Acad. Sci. USA 105, 20876-20881.
60. Rottenberg, S., Nygren, A. O., Pajic, M., et al. (2007). Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc. Natl. Acad. Sci. USA 104, 12117-12122. (Pubitemid 47185639)
61. Rottenberg, S., Jaspers, J. E., Kersbergen, A., et al. (2008). High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl. Acad. Sci. USA 105, 17079-17084.
62. Rulten, S. L., Cortes-Ledesma, F., Guo, L., et al. (2008). APLF (C2orf13) is a novel component of poly (ADP-ribose) signaling in mammalian cells. Mol. Cell. Biol. 28, 4620-4628. (Pubitemid 351977759)
63. Saal, L. H., Gruvberger-Saal, S. K., Persson, C., et al. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat. Genet. 40, 102-107.
64. Sakai, W., Swisher, E. M., Karlan, B. Y., et al. (2008). Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120. (Pubitemid 351317449)
65. Sanders, S. L., Portoso, M., Mata, J., et al. (2004). Methylation of histone H4 lysine 20 controls recruitment of Crb2 to sites of DNA damage. Cell 119, 603-614. (Pubitemid 39535749)
66. Sanderson, R. J., and Lindahl, T. (2002). Down-regulation of DNA repair synthesis at DNA single-strand interruptions in poly (ADP-ribose) polymerase-1 deficient murine cell extracts. DNA Repair (Amst.) 1, 547-558. (Pubitemid 34655712)
67. Sartori, A. A., Lukas, C., Coates, J., et al. (2007). Human CtIP promotes DNA end resection. Nature 450, 509-514. (Pubitemid 350190253)
68. Satoh, M. S., and Lindahl, T. (1992). Role of poly (ADP-ribose) formation in DNA repair. Nature 356, 356-358.
69. Schultz, L. B., Chehab, N. H., Malikzay, A., et al. (2000). p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151, 1381-1390. (Pubitemid 32047588)
70. Schultz, N., Lopez, E., Saleh-Gohari, N., et al. (2003). Poly (ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 31, 4959-4964. (Pubitemid 37441861)
71. Scully, R., Ganesan, S., Brown, M., et al. (1996). Location of BRCA1 in human breast and ovarian cancer cells. Science 272, 123-126.
72. Scully, R., Chen, J., Ochs, R. L., et al. (1997a). Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90, 425-435. (Pubitemid 27347233)
73. Scully, R., Chen, J., Plug, A., et al. (1997b). Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88, 265-275. (Pubitemid 28015875)
74. Scully, R., Ganesan, S., Vlasakova, K., et al. (1999). Genetic analysis of BRCA1 function in a defined tumor cell line. Mol. Cell 4, 1093-1099. (Pubitemid 30054915)
75. Shakya, R., Szabolcs, M., McCarthy, E., et al. (2008). The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc. Natl. Acad. Sci. USA 105, 7040-7045. (Pubitemid 351754526)
76. Silver, D. P., Richardson, A. L., Eklund, A. C., et al. (2010). Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 28, 1145-1153.
77. -/- mice: genome stabilization in immortalized cells by reintroduction of poly (ADP-ribose) polymerase cDNA. Proc. Natl. Acad. Sci. USA 96, 13191-13196.
78. Snouwaert, J. N., Gowen, L. C., Latour, A. M., et al. (1999). BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a Brca1 transgene. Oncogene 18, 7900-7907. (Pubitemid 30066235)
79. Sobhian, B., Shao, G., Lilli, D. R., et al. (2007). RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 316, 1198-1202. (Pubitemid 46877483)
80. Sorlie, T., Tibshirani, R., Parker, J., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 100, 8418-8423. (Pubitemid 36842560)
81. Sugimura, K., Takebayashi, S., Taguchi, H., et al. (2008). PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J. Cell. Biol. 183, 1203-1212.
82. Swisher, E. M., Sakai, W., Karlan, B. Y., et al. (2008). Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586. (Pubitemid 351556255)
83. Sy, S. M., Huen, M. S., and Chen, J. (2009). PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc. Natl. Acad. Sci. USA 106, 7155-7160.
84. Tassone, P., Tagliaferri, P., Perricelli, A., et al. (2003). BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer 88, 1285-1291. (Pubitemid 36606348)
85. Tassone, P., Di Martino, M. T., Ventura, M., et al. (2009). Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol. Ther. 8, 648-653.
86. Tulin, A., and Spradling, A. (2003). Chromatin loosening by poly (ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science 299, 560-562. (Pubitemid 36135152)
87. Turner, N. C., and Reis-Filho, J. S. (2006). Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25, 5846-5853. (Pubitemid 44453440)
88. Turner, N. C., Reis-Filho, J. S., Russell, A. M., et al. (2007). BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26, 2126-2132. (Pubitemid 46514749)
89. Tutt, A., Robson, M., Garber, J. E., et al. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244.
90. Wang, W., and Figg, W. D. (2008). Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol. Ther. 7, 1004-1005.
91. Wang, Z. Q., Stingl, L., Morrison, C., et al. (1997). PARP is important for genomic stability but dispensable in apoptosis. Genes Dev. 11, 2347-2358. (Pubitemid 27408532)
92. Wang, B., Matsuoka, S., Carpenter, P. B., et al. (2002). 53BP1, a mediator of the DNA damage checkpoint. Science 298, 1435-1438. (Pubitemid 35346146)
93. Wang, B., Matsuoka, S., Ballif, B. A., et al. (2007). Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 316, 1194-1198. (Pubitemid 46877482)
94. Ward, I. M., Minn, K., van Deursen, J., et al. (2003). p53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Mol. Cell. Biol. 23, 2556-2563. (Pubitemid 36351034)
95. Ward, I. M., Reina-San-Martin, B., Olaru, A., et al. (2004). 53BP1 is required for class switch recombination. J. Cell. Biol. 165, 459-464. (Pubitemid 38679611)
96. Westermark, U. K., Reyngold, M., Olshen, A. B., et al. (2003). BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks. Mol. Cell. Biol. 23, 7926-7936. (Pubitemid 37271488)
97. Williams, R. S., Green, R., and Glover, J. N. (2001). Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat. Struct. Biol. 8, 838-842. (Pubitemid 32923600)
98. Wong, A. K., Ormonde, P. A., Pero, R., et al. (1998). Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 17, 2279-2285. (Pubitemid 28515380)
99. Woodhouse, B. C., and Dianov, G. L. (2008). Poly ADP-ribose polymerase-1: an international molecule of mystery. DNA Repair (Amst.) 7, 1077-1086.
100. Wu, L. C., Wang, Z. W., Tsan, J. T., et al. (1996). Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet. 14, 430-440. (Pubitemid 26414587)
101. Xia, Y., Pao, G. M., Chen, H. W., et al. (2003). Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J. Biol. Chem. 278, 5255-5263. (Pubitemid 36801039)
102. Xia, B., Sheng, Q., Nakanishi, K., et al. (2006). Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 22, 719-729.
103. Xie, A., Hartlerode, A., Stucki, M., et al. (2007). Distinct roles of chromatin-associated proteins MDC1 and 53BP1 in mammalian doublestrand break repair. Mol. Cell 28, 1045-1057. (Pubitemid 350297033)
104. Xu, X., Qiao, W., Linke, S. P., et al. (2001). Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet. 28, 266-271. (Pubitemid 32626030)
105. Yang, Y. G., Cortes, U., Patnaik, S., et al. (2004). Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 23, 3872-3882. (Pubitemid 38725700)
106. Yu, X., Wu, L. C., Bowcock, A. M., et al. (1998). The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 273, 25388-25392. (Pubitemid 28443306)
107. Zhang, F., Fan, Q., Ren, K., et al. (2009a). PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol. Cancer Res. 7, 1110-1118.
108. Zhang, F., Ma, J., Wu, J., et al. (2009b). PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr. Biol. 19, 524-529.
109. Zhong, Q., Boyer, T. G., Chen, P. L., et al. (2002). Deficient nonhomologous endjoining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res. 62, 3966-3970. (Pubitemid 34791061)